Home » Brett Scott

Brett Scott

Brett Scott graduated last May with a degree in finance from Kansas State University, where he picked up an interest in biotech. He started his MBA this summer at K-State, and after another class had him using valuation methods to find values for small biotech companies, Brett decided to start his blog in an effort to not only satisfy his own interest, but to also get feedback from others in the investment world.

Brett Scott's Latest Articles

Understanding Cost of Capital in Biotechs' Valuation
on Jan 29, 2008
Will the Clouds Clear for Amgen?
on Jan 28, 2008 about AMGN
Gilead Keeps Going Strong
on Jan 25, 2008 about GILD
Correction and Clarification to Tysabri Post
on Jan 23, 2008 about BIIB, ELN, JNJ
Elan, Biogen Idec Won't Gain Much from Tysabri Approval
on Jan 21, 2008 about BIIB, ELN
Investors May Prefer to Stay Away from DNA
on Jan 15, 2008 about DNA
Forecast for ViroPharma's Pipeline: Mostly Shiny
on Jan 14, 2008 about VPHM
FDA Sets Date for Theravance Drug Review
on Jan 11, 2008 about THRX
A Win-Win for Isis, Genzyme in Cholesterol Drug Deal
on Jan 09, 2008 about GENZ, ISIS
Celgene Puts Drug Scare Behind It
on Jan 07, 2008 about CELG
Amgen's Bone Density Drug Needs to Prove Itself
on Dec 19, 2007 about AMGN
Three Reasons To Turn To Biotech In A Messy Market
on Nov 09, 2007 about BBH, IBB, PBE
Staph Buzz Spotlights Cubist, Pfizer, Encysive
on Oct 25, 2007 about CBST, ENCY, PFE
Gilead Continues To Shine, But Watch The Competition
on Oct 23, 2007 about GILD
3 Positives From Vanda's Conference Call
on Oct 11, 2007 about VNDA
NeurogesX, Vanda Would Do Well To Find Themselves A Partner
on Oct 01, 2007 about NGSX, VNDA
Two Important Lessons to be Learned from Sonus
on Sep 25, 2007 about SNUS
Celgene Offers Investors The Growth They Want
on Sep 16, 2007 about CELG
Is Biotech on the Verge of a Breakout?
on Sep 10, 2007 about BIIB
Now's The Time To Hop Aboard NeurogesX
on Sep 05, 2007 about NGSX
Sonus Is Undervalued At $4 - Call Options Are Attractive
on Aug 30, 2007 about SNUS
Vanda Pharmaceuticals: Finding Reassurance In Institutional Investors and Fair Value Calculations
on Aug 27, 2007 about VNDA
Helicos: To Buy or Not To Buy?
on Aug 23, 2007 about HLCS
Three Reasons to Be Optimstic on NeurogesX
on Aug 16, 2007 about NGSX
Vanda Pharmaceuticals' Pipeline Nearing FDA Stage
on Aug 14, 2007 about VNDA
Ziopharm: Too Early To Make A Call
on Jul 30, 2007 about ZIOP
Neurogesx: A Speculative Biotech Investment
on Jul 24, 2007 about NGSX
Genentech Suffering From A Lack of Short-Term Catalysts
on Jul 18, 2007 about DNA
DepoMed Demonstrates The Risks Of Small Biotech
on Jul 12, 2007 about DEPO
Celgene, Genentech, Gilead: Is Biotech Weakness Creating A Buying Opportunity?
on Jul 05, 2007 about CELG, DNA, GILD

Symbols:

Authors:

July 25, 2008 | Last Updated 21:02 ET

Contribute an Article Become a Seeking Alpha Contributor

Latest Commentson Brett Scott's Articles

Get Seeking Alpha Free Stock Alerts by Email!

Get Free Stock Alerts by Email!

Trading Center

Hedge Fund Jobs

Job Seekers:

Search jobs by category
Get job alerts by email or live feed
Apply online

See full list of jobs »

Employers

See all recruitment options
Get applications online or by email

Post a job »

Seeking Alpha

Brett Scott

Brett Scott's Latest Articles

Latest Commentson Brett Scott's Articles

Get Seeking Alpha Free Stock Alerts by Email!

Get Free Stock Alerts by Email!

Most Popular Feeds

ETFs

US Market

Long Ideas

Alt. Energy

Trading Center

Hedge Fund Jobs

Job Seekers:

Employers

Stock Market Opinion & Analysis